Innovative SARS-CoV-2 blockers completely prevent cell infections

Biopharmaceutical company Formycon AG and its academic partner, Professor Johannes Buchner of the University of Technology Munich, published the latest results on the innovative SARS-CoV-2 blocker FYB207.
based on Formycon's clinical experience in antibodies and antibody fusion proteins, the company began developing the ACE2 antibody fusion protein (FYB207) in March 2020, shortly after the COVID-19 pandemic in Europe.
SARS-CoV-2 uses ACE2 on the surface of human cells as an entry point for respiratory infections.
this, Formycon uses a computer-aided structural design to bind the human ACE2 protein to the human antibody component, resulting in a very effective SARS-CoV-2 blocker called ACE2-IgG-Fc.
the manufacturability, stability and viral inhibition of different variants of viral blockers were studied on the laboratory scale.
in-body tests using the SARS-CoV-2 isolated strain and the original SARS-CoV in 2003 have shown that Formycon's ACE2 antibody fusion protein binds effectively to SARS coronavirus and completely prevents cell infection.
, ACE2 antibody fusion proteins minimize the escape of viruses through mutations compared to vaccines and therapeutic antibodies.
FYB207 also has an inherent enzyme activity that provides additional protection for the lungs and cardiovascular systems of patients with symptoms.
。